Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

Next Previous
Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANB 032 (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARISE-AD
  • Sponsors AnaptysBio

Most Recent Events

  • 14 Feb 2025 Status changed from active, no longer recruiting to discontinued.because ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis .
  • 11 Dec 2024 Primary endpoint (Proportion of subjects who achieve 75% reduction (improvement) from Baseline in EASI-75 as Week 14) has not been met, according to an AnaptysBio media release.
  • 14 Aug 2024 According to an AnaptysBio media release, company announced the pricing of an underwritten offering of 2,750,498 shares, the gross proceeds from this offering are expected to be approximately $100 million. The proceeds intended to be used primarily to accelerate and support the enablement of Phase 3 trials for ANB032in Phase 2b development in atopic dermatitis, rosnilimab in Phase 2b development in rheumatoid arthritis and Phase 2 development in ulcerative colitis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top